# üìù Question: Explain the provisions relating to compulsory licensing under the Patents Act, 1970, and discuss the Natco v. Bayer case. (10 Marks)

---

# ‚úçÔ∏è Answer:

## üìå Synopsis

<div style="margin-left: 20px;">

1. **Introduction**

2. **3 Provisions for Compulsory Licensing** (Sections 84, 92, 92A)

3. **3 Grounds Under Section 84**

4. **6 Terms and Conditions of Compulsory Licenses**

5. **Natco Pharma v. Bayer (2012)** - Landmark case

6. **Conclusion**

</div>

---

## üéØ Introduction

<div style="margin-left: 20px;">

Compulsory licensing is a mechanism that allows the government to authorize the use of a patented invention by a third party without the patent owner's consent. This powerful tool balances the exclusive rights of patent owners with public interest considerations, particularly access to essential goods like medicines. The Patents Act, 1970, contains detailed provisions on compulsory licensing that reflect India's commitment to both promoting innovation and ensuring public welfare.

</div>

---

> ## üìä Visual Aide: Compulsory Licensing Structure
>
> ```
> Compulsory Licensing
>          |
>          ‚îú‚îÄ‚îÄ Section 84 - General (After 3 years)
>          ‚îÇ    ‚îú‚îÄ‚îÄ Reasonable requirements not met
>          ‚îÇ    ‚îú‚îÄ‚îÄ Not at affordable price
>          ‚îÇ    ‚îî‚îÄ‚îÄ Not worked in India
>          ‚îÇ
>          ‚îú‚îÄ‚îÄ Section 92 - Special Cases (No waiting)
>          ‚îÇ    ‚îú‚îÄ‚îÄ National emergency
>          ‚îÇ    ‚îú‚îÄ‚îÄ Extreme urgency
>          ‚îÇ    ‚îî‚îÄ‚îÄ Public non-commercial use
>          ‚îÇ
>          ‚îî‚îÄ‚îÄ Section 92A - Export
>               ‚îî‚îÄ‚îÄ For countries lacking capacity
> ```

---

> ## üß† Mnemonics for Compulsory Licensing
>
> **3 Provisions: "GSE"**
> - **G** - General (Section 84) | **S** - Special Cases (Section 92) | **E** - Export (Section 92A)
>
> **3 Grounds (Section 84): "RAW"**
> - **R** - Reasonable requirements not satisfied | **A** - Affordable price not available | **W** - Worked in India not done
>
> **6 CL Conditions: "SNNPDR"**
> - **S** - Scope limited | **N** - Non-exclusive | **N** - Non-assignable | **P** - Predominantly domestic | **D** - Duration limited | **R** - Remuneration adequate

---

## üìú 3 Provisions for Compulsory Licensing

---

### Provision 1: Section 84 - General Grounds

<div style="margin-left: 20px;">

**Timing:** After **3 years from grant of patent**

**Who Can Apply:** Any interested person

#### 3 Grounds for Compulsory License:

<div style="margin-left: 20px;">

**Ground 1: Reasonable Requirements Not Satisfied**

<div style="margin-left: 20px;">

The reasonable requirements of the public with respect to patented invention have not been satisfied.

**What This Means:** Invention not available in sufficient quantity, Not available at reasonably affordable prices, Demand exceeds supply

</div>

<br>

**Ground 2: Not Available at Reasonably Affordable Price**

<div style="margin-left: 20px;">

The patented invention is not available to public at reasonably affordable price.

</div>

<br>

**Ground 3: Not Worked in India**

<div style="margin-left: 20px;">

The patented invention is not worked (manufactured) in territory of India.

**Important:** Simply importing doesn't satisfy working requirement. Local manufacturing encouraged.

</div>

</div>

#### Prior Negotiation Required (Section 84(6)):

<div style="margin-left: 20px;">

Controller won't grant compulsory license unless:
- Applicant made efforts to obtain voluntary license
- Efforts unsuccessful within reasonable period (‚âà6 months)

**Exception:** Prior negotiation waived for national emergency, extreme urgency, public non-commercial use, anti-competitive practices.

</div>

</div>

---

### Provision 2: Section 92 - Special Cases

<div style="margin-left: 20px;">

**NO 3-year waiting period required**

#### 3 Circumstances:

<div style="margin-left: 20px;">

**1. National Emergency**

**2. Extreme Urgency**

**3. Public Non-Commercial Use**

</div>

**Examples:** Health epidemics (HIV/AIDS, TB, COVID-19), Natural disasters, War or national security threat

**Special Feature:** No prior negotiation required.

</div>

---

### Provision 3: Section 92A - Export License

<div style="margin-left: 20px;">

For countries lacking pharmaceutical manufacturing capacity:
- That country issues compulsory license
- India can grant license to manufacture and export
- Helps countries unable to manufacture themselves

</div>

---

## üìã 6 Terms and Conditions of Compulsory Licenses

<div style="margin-left: 20px;">

**Condition 1: Limited Scope and Duration** - License limited to purpose, reasonable duration

**Condition 2: Non-Exclusive** - Always non-exclusive, patent owner can still work patent

**Condition 3: Non-Assignable** - Cannot be independently transferred, only with business

**Condition 4: Predominantly Domestic Market** - Production mainly for domestic, not export (except Section 92A)

**Condition 5: Reasonable Duration** - Not perpetual, subject to review

**Condition 6: Adequate Remuneration (Section 90)** - Licensee must pay (typically 2-7% of net sales)

</div>

---

## ‚öñÔ∏è Landmark Case: Natco Pharma v. Bayer (2012) ‚≠ê‚≠ê‚≠ê

<div style="margin-left: 20px;">

### Case Details:

<div style="margin-left: 20px;">

**Drug:** Nexavar (Sorafenib Tosylate) - Cancer drug (kidney/liver)

**Patentee:** Bayer Corporation (Germany)

**Applicant:** Natco Pharma (India)

**Decision:** March 2012

**Status:** India's FIRST compulsory license

</div>

### 6 Critical Facts:

<div style="margin-left: 20px;">

**Fact 1: Exorbitant Pricing**

<div style="margin-left: 20px;">
Bayer's price: ‚Çπ2.8 lakh per month per patient - Unaffordable for most Indians
</div>

<br>

**Fact 2: Limited Availability**

<div style="margin-left: 20px;">
Only 2% of patients who needed drug could access it - Only ~200 patients per month
</div>

<br>

**Fact 3: Not Worked in India**

<div style="margin-left: 20px;">
Bayer importing, not manufacturing locally - No production facility in India
</div>

<br>

**Fact 4: Natco's Offer**

<div style="margin-left: 20px;">
Offered at ‚Çπ8,800 per month - 97% price reduction - Make available to thousands
</div>

<br>

**Fact 5: Prior Negotiation Attempted**

<div style="margin-left: 20px;">
Natco approached Bayer for voluntary license - Negotiations failed
</div>

<br>

**Fact 6: Patient Need**

<div style="margin-left: 20px;">
Life-saving drug for advanced cancer - No alternative treatment available
</div>

</div>

### Controller's Decision - LICENSE GRANTED ‚úÖ

<div style="margin-left: 20px;">

#### 4 Key Findings:

<div style="margin-left: 20px;">

**Finding 1: Reasonable Requirements NOT Met**

<div style="margin-left: 20px;">
Only 2% access insufficient, ‚Çπ2.8 lakh unaffordable, Patient assistance inadequate (200 patients only)
</div>

<br>

**Finding 2: NOT Reasonably Affordable**

<div style="margin-left: 20px;">
‚Çπ2.8 lakh not reasonable in Indian context, "Reasonable" interpreted locally not globally
</div>

<br>

**Finding 3: NOT Worked in India**

<div style="margin-left: 20px;">
Merely importing - no local manufacturing, Section 83: Patents not granted just for importation
</div>

<br>

**Finding 4: Prior Negotiation Done**

<div style="margin-left: 20px;">
Natco approached Bayer, Bayer offered unreasonable terms, Requirement satisfied
</div>

</div>

</div>

### 5 Terms of the Compulsory License:

<div style="margin-left: 20px;">

**Term 1: Royalty** - Natco must pay Bayer 6% of net sales

**Term 2: Price Cap** - Natco must sell at ‚Çπ8,800 per month

**Term 3: Minimum Supply** - Supply to at least 600 patients/month initially

**Term 4: Quality Assurance** - Ensure good quality, comply with regulatory standards

**Term 5: Free Supply** - Provide drug free to 600 patients annually who cannot afford

</div>

### 8 Significance Points (Mnemonic: "FIAT WIEP"):

<div style="margin-left: 20px;">

**F** - First CL in India | **I** - Interpretation of "affordable" | **A** - Access to medicines (97% price cut) | **T** - TRIPS flexibilities used | **W** - Working requirement clarified | **I** - India's policy direction | **E** - Evergreening prevented | **P** - Price reduction achievement

</div>

### Aftermath:

<div style="margin-left: 20px;">

**Appeal:** Bayer appealed to IPAB. IPAB **upheld** compulsory license (2013) with minor modifications.

**Impact:** Natco made Nexavar affordable, Thousands gained access, Precedent established, Demonstrated TRIPS flexibilities work

</div>

</div>

---

## üéØ Conclusion

<div style="margin-left: 20px;">

Compulsory licensing is critical tool for balancing patent rights with public interest, particularly ensuring access to essential medicines. The Natco v. Bayer case demonstrated India is willing to use this tool effectively when patented drugs are unaffordable or unavailable.

**4 Key Lessons:**
1. Patent rights are not absolute
2. Public health can override exclusive rights
3. TRIPS flexibilities can be used effectively
4. Reasonable compensation still provided

For developing countries like India, compulsory licensing remains essential safeguard to ensure patent protection doesn't come at cost of access to life-saving medicines. Natco case serves as model for how this balance can be achieved in practice.

</div>

---

> ## üìö Key Facts Summary
>
> | **Aspect** | **Details** |
> |-----------|------------|
> | **Sections** | 84 (General), 92 (Special), 92A (Export) |
> | **3 Grounds** | RAW (Reasonable, Affordable, Worked) |
> | **6 Conditions** | SNNPDR |
> | **Natco Case** | First CL in India (2012) |
> | **Price Reduction** | ‚Çπ2.8L ‚Üí ‚Çπ8,800 (97%) |
> | **Royalty** | 6% of net sales |
> | **Decision** | Upheld by IPAB (2013) |
>
> **üéØ Remember:** "RAW" grounds | "GSE" provisions | Natco reduced price by 97%!
